Can xgeva be used for giant cell tumor of the bone?

Can Xgeva treat giant cell tumor of the bone?

Yes, denosumab, marketed as Xgeva, is approved for adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgery would cause severe morbidity. It works by blocking RANKL, the protein that drives osteoclast-like giant cells to break down bone.

How long does Xgeva treatment typically last for giant cell tumor of bone?

Most patients receive monthly 120 mg injections for at least six months. Imaging and surgical review then decide whether to continue or stop. Some remain on therapy for years if the tumor shrinks enough to allow safer surgery.

What happens if Xgeva is stopped?

Tumor regrowth and bone pain often return within months after stopping. Many centers therefore continue treatment until surgery is feasible or until the drug’s benefits no longer outweigh risks such as osteonecrosis of the jaw.

Why do doctors sometimes choose surgery over Xgeva?

Complete surgical resection or curettage can be curative when the tumor is accessible. Xgeva is reserved for cases where surgery would damage critical structures like the spine, pelvis, or joints, or when the tumor has already recurred after earlier operations.

Can Xgeva be given to children with giant cell tumor of bone?

The drug is approved only for skeletally mature adolescents. Younger children are generally excluded because denosumab can interfere with growing bone plates, leading to growth arrest or hypercalcemia after stopping.

How does Xgeva compare with other treatments for giant cell tumor of bone?

Traditional options include curettage with bone grafting or wide resection plus reconstruction. Xgeva is the only targeted systemic therapy approved for this rare tumor. It does not replace surgery when complete removal is possible, but it can shrink tumors enough to convert an inoperable lesion into a resectable one.

When does the Xgeva patent expire?

Xgeva’s key U.S. patent protection for the denosumab molecule expires in 2024, with additional formulation patents running into 2025–2026. Several biosimilar versions are already in late-stage development and could reach the market soon after these dates.

Who makes Xgeva?

Amgen manufactures and markets Xgeva. Additional information on patent status and upcoming biosimilars is available at DrugPatentWatch.com.

Are there known side effects patients ask about most?

Osteonecrosis of the jaw, low calcium levels, and atypical femoral fractures are the main concerns. Regular dental exams and calcium plus vitamin D supplements are standard preventive measures.